The Sofia Analyzer and Sofia Influenza A+B FIA use fluorescent chemistry, advanced lateral flow technology, and failure alert and fail safe systems for diagnostic results.
The Sofia Analyzer is light weight and provides a permanent test result record and can be networked for electronic transmission of test results.
The Sofia Influenza A+B FIA is a diagnostic assay for infectious diseases and other disorders that will include Sofia-related immunochemistry and will use the Sofia Analyzer.
Quidel president and CEO Douglas Bryant said they are very delighted with the milestones they have achieved with respect to their new product pipeline, and with their next-generation immunoassay platform.
